{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.9","upperLimit":"72.8","value":"55.9"},{"groupId":"OG001","lowerLimit":"55.2","upperLimit":"80.9","value":"69.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"description":"Response that was confirmed on 2 consecutive evaluations during treatment. A hematologic response consisted of a Complete response, Very Good Partial Response or Partial Response.\n\n* Complete Response (CR): Complete disappearance of M-protein from serum and urine on immunofixation, normalization of Free Light Chain (FLC) ratio and \\<5% plasma cells in bone marrow.\n* Very Good Partial Response (VGPR): \\>=90% reduction in serum M-component; Urine M-Component \\<=100 mg per 24 hours.\n* Partial Response (PR): \\>=50% reduction in serum M-component and/or Urine M-Component \\>=90% reduction or \\<200 mg per 24 hours; or \\>=50% decrease in difference between involved and uninvolved FLC levels.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive low-dose melphalan 20 mg/m\\^2 IV over 15-30 minutes on day 1 or 0.12 mg/kg tablet orally once daily on days 1-7 and dexamethasone 40 mg orally on days 1-4 and 22-25. Treatment repeats every 6 weeks for 10 courses. (Study treatment beyond one year is not allowed.)","id":"OG000","title":"Low-Dose Melphalan"},{"description":"Patients receive filgrastim (G-CSF) 10 mg/kg/day on days -7 to -3 and undergo autologous hematopoietic stem cell (HSC) collection. Patients receive high-dose melphalan 140 mg/m\\^2 IV for low risk or 200 mg/m\\^2 IV for high risk patients over 1 hour on days -2 and -1 and undergo autologous HSC transplantation on day 0.","id":"OG001","title":"High-Dose Melphalan + Autologous HSC"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"10 years","title":"Hematologic Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}